We present the case of a 19-year-old female with severe hypogammaglobulinemia after having had treatment with rituximab for idiopathic thrombocytopenic purpura requiring intravenous immunoglobulins. She was admitted with the diagnosis of left-sided pneumonia with parapneumonic effusion. The patient was treated with piperacillin/tazobactam after having a poor response to co-amoxiclav. The patient had been tested for immunoglobulin levels, and the levels were very low. She has a history of ITP for which she received steroids. She also received rituximab for the same on four separate occasions, and the last one was about 1 year ago
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
Rituximab (RTX) is an anti-CD20 monoclonal antibody that targets B cells-from the immature pre-B-cel...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
AbstractRituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, is an effective treatment for haem...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
The occurrence of secondary hypogammaglobulinemia (SH) after chemo-immunotherapy represents a potent...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
Presentation of Case: A 33 years-old female with limited (otorhinolaryngological manifestations) bio...
A 72-year-old Japanese woman diagnosed with antineutrophil cytoplasmic antibody (ANCA)-associated va...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
Rituximab (RTX) is an anti-CD20 monoclonal antibody that targets B cells-from the immature pre-B-cel...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
AbstractRituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, is an effective treatment for haem...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
The occurrence of secondary hypogammaglobulinemia (SH) after chemo-immunotherapy represents a potent...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
Presentation of Case: A 33 years-old female with limited (otorhinolaryngological manifestations) bio...
A 72-year-old Japanese woman diagnosed with antineutrophil cytoplasmic antibody (ANCA)-associated va...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...